155 related articles for article (PubMed ID: 9258244)
21. Multiple sclerosis: death receptor expression and oligodendrocyte apoptosis in established lesions.
Cannella B; Gaupp S; Omari KM; Raine CS
J Neuroimmunol; 2007 Aug; 188(1-2):128-37. PubMed ID: 17610960
[TBL] [Abstract][Full Text] [Related]
22. Oligodendrogliopathy in Multiple Sclerosis: Low Glycolytic Metabolic Rate Promotes Oligodendrocyte Survival.
Rone MB; Cui QL; Fang J; Wang LC; Zhang J; Khan D; Bedard M; Almazan G; Ludwin SK; Jones R; Kennedy TE; Antel JP
J Neurosci; 2016 Apr; 36(17):4698-707. PubMed ID: 27122029
[TBL] [Abstract][Full Text] [Related]
23. Oligodendrocyte and axon pathology in clinically silent multiple sclerosis lesions.
Mews I; Bergmann M; Bunkowski S; Gullotta F; Brück W
Mult Scler; 1998 Apr; 4(2):55-62. PubMed ID: 9599334
[TBL] [Abstract][Full Text] [Related]
24. Oligodendroglial lineage cells express nuclear p57kip2 in multiple sclerosis lesions.
Pfeifenbring S; Metz I; Kremer D; Küry P; Hartung HP; Brück W
Glia; 2013 Aug; 61(8):1250-60. PubMed ID: 23828667
[TBL] [Abstract][Full Text] [Related]
25. Mechanisms of damage to myelin and oligodendrocytes and their relevance to disease.
Merrill JE; Scolding NJ
Neuropathol Appl Neurobiol; 1999 Dec; 25(6):435-58. PubMed ID: 10632895
[TBL] [Abstract][Full Text] [Related]
26. Remyelinating strategies in multiple sclerosis.
Luessi F; Kuhlmann T; Zipp F
Expert Rev Neurother; 2014 Nov; 14(11):1315-34. PubMed ID: 25331418
[TBL] [Abstract][Full Text] [Related]
27. NG2-positive oligodendrocyte progenitor cells in adult human brain and multiple sclerosis lesions.
Chang A; Nishiyama A; Peterson J; Prineas J; Trapp BD
J Neurosci; 2000 Sep; 20(17):6404-12. PubMed ID: 10964946
[TBL] [Abstract][Full Text] [Related]
28. Adaptive human immunity drives remyelination in a mouse model of demyelination.
El Behi M; Sanson C; Bachelin C; Guillot-Noël L; Fransson J; Stankoff B; Maillart E; Sarrazin N; Guillemot V; Abdi H; Cournu-Rebeix I; Fontaine B; Zujovic V
Brain; 2017 Apr; 140(4):967-980. PubMed ID: 28334918
[TBL] [Abstract][Full Text] [Related]
29. Oligodendrocytes and the early multiple sclerosis lesion.
Prineas JW; Parratt JD
Ann Neurol; 2012 Jul; 72(1):18-31. PubMed ID: 22829266
[TBL] [Abstract][Full Text] [Related]
30. Patterns of oligodendroglia pathology in multiple sclerosis.
Ozawa K; Suchanek G; Breitschopf H; Brück W; Budka H; Jellinger K; Lassmann H
Brain; 1994 Dec; 117 ( Pt 6)():1311-22. PubMed ID: 7820568
[TBL] [Abstract][Full Text] [Related]
31. Are electrophysiological and oligodendrocyte alterations an element in the development of multiple sclerosis at the same time as or before the immune response?
Ortiz GG; Mireles-Ramírez MA; Pacheco-Moisés FP; Ramírez-Jirano LJ; Bitzer-Quintero OK; Delgado-Lara DLC; Flores-Alvarado LJ; Mora-Navarro MA; Huerta M; Torres-Mendoza BMG
Int J Neurosci; 2021 Dec; 131(12):1221-1230. PubMed ID: 32571126
[TBL] [Abstract][Full Text] [Related]
32. Multiple sclerosis: lessons from neuropathology.
Lucchinetti CF; Brueck W; Rodriguez M; Lassmann H
Semin Neurol; 1998; 18(3):337-49. PubMed ID: 9817538
[TBL] [Abstract][Full Text] [Related]
33. Cells of the oligodendroglial lineage, myelination, and remyelination.
Miron VE; Kuhlmann T; Antel JP
Biochim Biophys Acta; 2011 Feb; 1812(2):184-93. PubMed ID: 20887785
[TBL] [Abstract][Full Text] [Related]
34. The Role of Sex Hormones in Multiple Sclerosis.
Avila M; Bansal A; Culberson J; Peiris AN
Eur Neurol; 2018; 80(1-2):93-99. PubMed ID: 30343306
[TBL] [Abstract][Full Text] [Related]
35. Activation of NF-kappaB and c-jun transcription factors in multiple sclerosis lesions. Implications for oligodendrocyte pathology.
Bonetti B; Stegagno C; Cannella B; Rizzuto N; Moretto G; Raine CS
Am J Pathol; 1999 Nov; 155(5):1433-8. PubMed ID: 10550297
[TBL] [Abstract][Full Text] [Related]
36. Activating transcription factor 6α deficiency exacerbates oligodendrocyte death and myelin damage in immune-mediated demyelinating diseases.
Stone S; Wu S; Jamison S; Durose W; Pallais JP; Lin W
Glia; 2018 Jul; 66(7):1331-1345. PubMed ID: 29436030
[TBL] [Abstract][Full Text] [Related]
37. Promoting myelin repair and return of function in multiple sclerosis.
Zhang J; Kramer EG; Asp L; Dutta DJ; Navrazhina K; Pham T; Mariani JN; Argaw AT; Melendez-Vasquez CV; John GR
FEBS Lett; 2011 Dec; 585(23):3813-20. PubMed ID: 21864535
[TBL] [Abstract][Full Text] [Related]
38. Tumour necrosis factor alpha mRNA expression in early multiple sclerosis lesions: correlation with demyelinating activity and oligodendrocyte pathology.
Bitsch A; Kuhlmann T; Da Costa C; Bunkowski S; Polak T; Brück W
Glia; 2000 Feb; 29(4):366-75. PubMed ID: 10652446
[TBL] [Abstract][Full Text] [Related]
39. Interleukin-11 potentiates oligodendrocyte survival and maturation, and myelin formation.
Zhang Y; Taveggia C; Melendez-Vasquez C; Einheber S; Raine CS; Salzer JL; Brosnan CF; John GR
J Neurosci; 2006 Nov; 26(47):12174-85. PubMed ID: 17122042
[TBL] [Abstract][Full Text] [Related]
40. Premyelinating oligodendrocytes in chronic lesions of multiple sclerosis.
Chang A; Tourtellotte WW; Rudick R; Trapp BD
N Engl J Med; 2002 Jan; 346(3):165-73. PubMed ID: 11796850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
